HOLL - To the Moon ab 2021

Hollister Biosciences hat für mich ein sehr großes Potential und ist im Cannabis-Sektor noch unbekannt und sehr unterbewertet. Schaut mach sich die Entwicklung seit Ende 2020 an, zieht der Umsatz enorm an.

Für das Jahr 2021 rechne ich mit einen Umsatz von ca. 120 Mio. CAD, bei gerade mal einer Market Cap von derzeit ca. 68 Mio. CAD. Die Bewertung von HOLL, mit einem Shareprice von 0,26 CAD, ist derzeit absolut unterbewertet.

Heute hat HOLL sein Q1 2021 veröffentlicht und ich rechne ab jetzt mit steigenden Preisen.

Quartals-Umsatzentwicklung in Dollar:
8,47 Mio - Juni 2020
9,48 Mio - September 2020
11,71 Mio - Dezember 2020
23,09 Mio - März 2021 und ab jetzt positives Ergebnis und Cash-Bestand > 6 Mio

Hier der Link zum Forum in CAN:

ceo.ca/holl


     

hollistercannabisco.com/

https://www.youtube.com/watch?v=Vei8K2xfh6U

Und nun die offizielle News. Ich bin gespannt, wie CAN darauf reagiert.
ceo.ca/@newswire/...iosciences-inc-reports-first-quarter-2021

Hollister Biosciences Inc. Reports First Quarter 2021 Financial Results

First quarter revenue was USD $23.1 million compared to USD $0.95 million in the first quarter of 2020 and up 97% sequentially from USD $11.7 million in the fourth quarter of 2020

First quarter net income was USD $2.0 million compared to a net loss of USD $2.2 million in the first quarter of 2020

Adjusted EBITDA was USD $2.80 million in the first quarter compared to a loss of USD $1.1 million in the first quarter of 2020

VANCOUVER, BC, June 1, 2021 /CNW/ - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 95 dispensaries throughout Arizona, today reported its financial and operating results for the first quarter of 2021.  All financial information is presented in U.S. dollars unless otherwise indicated.

Hollister Biosciences Inc. Logo (CNW Group/Hollister Biosciences Inc.)

First Quarter 2021 Financial Results

Total revenue in the first quarter was $23.1 million compared to $0.95 million in the first quarter of 2020 and up 97% sequentially from $11.7 million in the fourth quarter of 2020

Net income in the first quarter was $2.0 million compared to a net loss of $2.2 million in the first quarter of 2020

Adjusted EBITDA was $2.80 million in the first quarter compared to a loss of $1.1 million in the first quarter of 2020

First Quarter 2021 Business Highlights

On March 2nd, 2021, Hollister announced the closing of its brokered private placement of 21,635,094 Special Warrants at a price of CDN $0.365 per Special Warrant, raising gross proceeds of CDN $7.9 million
On March 8th, 2021, Hollister was pleased to announce that its direct-to-consumer delivery platform, Dreamy Delivery, was the official delivery platform of the 2021 Emerald Cup Awards

Venom Extracts ("Venom") product suite is a category leader in Arizona, accounting for up to 30 percent of category sales state-wide. Venom is positioned for continued growth in Arizona, it has a strong brand recognition and distribution network, with products in the vast majority of dispensaries statewide.

Venom Extracts operates a 11K sq. ft. facility located in Phoenix, AZ which can produce approximately 5 million grams of extract annually in its current and >15 million grams with planned equipment and production enhancements.

Arizona is one of the largest medical marijuana markets in the world with over $1B in 2020 sales. Legal sales of adult-use cannabis in Arizona commenced midday on Friday January 22nd, several months ahead of industry expectations, and the fastest that any of the 15 states with recreational marijuana has gone from voter approval to actual sales. The state realized over $2.9M in recreational sales within 10 days of legalization. "Marijuana Business Daily projects that the state's recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024."

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing. Our products are sold in 370 dispensaries across Arizona and California. Hollister Biosciences wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona.

Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA, birthplace of the "American Biker".

Website:  www.hollisterbiosciences.co

Cision View original content to download multimedia:www.prnewswire.com/news-releases/...ial-results-301302827.html

SOURCE Hollister Biosciences Inc.

Cision View original content to download multimedia: www.newswire.ca/en/releases/archive/June2021/01/c4955.html

HOLL ist für mich ein absolutes Long-Invest.

Schaue ich mir die Umsätze für das Q1 an und berücksichtige dabei, dass dieses Q1 noch nicht die vollständigen Umsätze wiederspiegelt, da für fast einen Monat die Umsätze für die nicht-medizinischen MJ aus Arizona fehlen und berücksichtige die Wachstumsrate bei HOLL, ist meine Prognose für das vollständige Q2 bei ca. 28 - 30 Mio. USD.

HOLL wird 2021 Umsätze von über 100 Mio. USD erzielen. Aus meiner Sicht wird der Shareprice bei HOLL im Jahre 2022 bei mehreren Dollar liegen. (Achtung meine Einschätzung, keine Kaufempfehlung!!)    

hier mal eine gute Darstellung aus dem CAN-Forum von "TheBar10der"

Who ever is looking here but hasn't bought yet. Go look at the other plays in the Cannabis Top 20-30 and see their SP and MC's - Marktbegleiter: 4front, Cweb, Planet13 and so on
4front who now has less sales than HOLL is over $900 mil MC and was $1.5 billion prior to the sector drop. HOLL ain't even 1x sales lol

HOLL needs to be $0.42, just to be at 1x sales  :)  2x $0.84 SP - 3x $1.26 - 4x $1.68
industry avg atm 5x = $2.10  yet we are a $0.34 sp?

ceo.ca/holl?f120bd6df0a7

Mein Mindest-Kursziel für HOLL in 2021 liegt bei 1,05 CAD = 0,71 € was eine 2,5 fache Bewertung im Verhältnis zum Umsatz entspricht. Was mindestens im Ansatz eine faire Bewertung wäre. Der Branchendurchschnitt liegt teilweise bei dem 4 bis 8 fachen. Nun warten wir mal ab, wie das Q2 abschneidet.

für Arizona und California - Cannabis Sales. Gute Aussichten für das Q2

www.newcannabisventures.com/...bis-sales-accelerate-in-april/

Arizona

Arizona transitioned to adult-use in late January, but this is the first month that BDSA included adult-use sales. Total cannabis sales grew 68% to $124.9 million, with adult-use representing $52.8 million. Medical cannabis sales fell 17% to $72.1 million. Growth was strong across all categories, but the highest growth by far was in pre-rolls, which gained 156%.

California

Sales soared 42% in April to $356.8 million, growth that was by far the strongest since the pandemic. It may be slightly overstated due to a dip in April a year ago from March. Flower grew in line with overall sales as did ingestibles, while concentrates were slower at 32% and pre-rolls were much stronger at 93%. The strength in pre-rolls is partially related to the dip a year ago when the pandemic was in its early days.

Hollister Biosciences Inc. Announces Launch of Pre-Roll Production and Distribution in Arizona

VANCOUVER, BC, June 28, 2021 /CNW/ - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") a diversified cannabis branding company is pleased to announce that it has commenced pre-roll production and distribution in Arizona to complement the Company's existing cannabis concentrate product suite in the state through its wholly owned Venom Extracts ("Venom") subsidiary.

Pre-roll production will initially be launched for existing and new white-label customers and will be expanded to include branded offerings in Q3 that leverage Venom's strong existing brand equity in the state. The company has prepared for initial production of up to 10,000 units per day, with plans to expand capacity to 30,000 units per day by Q4.

www.prnewswire.com/news-releases/...in-arizona-301320813.html

"As a result of adult use legalization in Arizona, we have witnessed growing consumer demand for pre-rolls in the state. Integrating our capabilities and brands between California and Arizona has been a key operational initiative for the Company and we are proud to share this exciting update. We look forward to  introducing our California Hashbone pre-roll brand and our brand partners into Arizona to broaden our higher margin product offerings throughout the state", shared Carl Saling, Co-Founder and CEO of Hollister.

Arizona Market

The state boasts a population of 7.3 million, approximately 70% of which are of legal consumption age, which makes it the 5th most populous state with an active legal adult-use market. Arizona is one of the largest medical marijuana markets in the world with over $1 billion in 2020 sales. The state has nearly 308,000  registered medical patients, making it the third largest medical program in absolute terms, and the second highest in terms of patient penetration rate. Legal sales of adult-use cannabis in Arizona commenced midday on Friday January 22nd, several months ahead of industry expectations, and the fastest that any of the 15 states with recreational marijuana has gone from voter approval to actual sales. The state realized over $2.9 million in recreational sales within 10 days of legalization. "Marijuana Business Daily projects that the state's recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024."

"Arizona transitioned to adult-use in late January, but this is the first month that BDSA included adult-use sales. Total cannabis sales grew 68% to $124.9 million, with adult-use representing $52.8 million. Medical cannabis sales fell 17% to $72.1 million. Growth was strong across all categories, but the highest growth by far was in pre-rolls, which gained 156%." - New Cannabis Ventures

Venom Highlights

In March 2020 Hollister Biosciences completed the acquisition of Venom Extracts, one of the industry's premier award-winning cannabis concentrate brands. Venom sales were consolidated with Hollister's sales starting after the closing in March and contributing approximately 95% of the Company's overall sales. Venom's product suite is a category leader in Arizona with over 4 million grams sold in 2020, accounting for up to 30 percent of category sales state-wide (per BDS Analytics). Venom is positioned for continued growth in Arizona, it has a strong brand recognition and distribution network, with products in the vast majority of dispensaries statewide.

Venom operates an 11K sq. ft. facility located in Phoenix, AZ which can produce approximately 5 million grams of extract annually in its current configuration. With planned equipment and production enhancements its expected production capacity will be greater than 15 million grams of concentrate products and over 8 million pre-rolls per year.

In 2020 Venom produced greater than 4 million grams of product
In Q1 2021 Venom produced approximately 2 million grams of product

This expansion reinforces the company's focus on operational efficiencies and profit margins through product mix and same customer sales. Adding Pre-Rolls as the next product category for Arizona leverages existing capabilities from California, and a large existing distribution network to enhance revenue and profitability of the Arizona operations. The Company looks forward to sharing additional details as this initiative progresses.

Nachdem in den US letzte Woche, nun endlich auch in CAN der Gap-Close. Laut Chart-Technik sollte es jetzt rauf gehen. Pünktlich zum Ende des 2.Quartals.

So unterbewertet ist HOLL aktuell. Ein Witz, dass wird sich bald ändern

cdn-ceo-ca.s3.amazonaws.com/1gdur2m-imbored.jpg

Weitere sehr gute Entwicklung in Arizona und California.

www.newcannabisventures.com/...ed-growth-during-the-pandemic/

Die Mai-Sales sind nach den starken April-Zahlen auf einem sehr hohen Niveau.

Das Q2 von HOLL sollte sehr stark ausfallen!

Arizona
Arizona transitioned to adult-use in late January, but this is the second month that BDSA included adult-use sales. Total cannabis sales grew 32% to $122.9 million, with adult-use representing $53.9 million. Medical cannabis sales fell 26% to $69 million. Sequentially, overall growth fell 1.6%, with medical falling 4% and adult-use increasing 2%. Growth was strong across all categories, but the highest growth by far was in pre-rolls, which gained 157%.

California
Annual sales grew 20.6% to $349.6 million, down 2% from the record level in April. Growth in most categories was 16-19%, with pre-rolls growing 57.8% from a year ago, reaching almost 13% of overall sales.

ceo.ca/@newswire/...iences-inc-added-to-horizons-us-marijuana

Hollister Biosciences Inc. Added to Horizons US Marijuana Index ETF and Included in Solactive US Marijuana Companies Index

VANCOUVER, BC, July 13, 2021 /CNW/ - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") a diversified cannabis branding company is pleased to announce that it was added as an index constituent in the Solactive US Marijuana Companies Index (the "Index") effective as of the US market open on June 21, 2021 as part of the Index's June, 2021 quarterly rebalancing and as a result is now a holding in the Horizons US Marijuana Index ETF (NEO: HMUS).
Solactive offers the full spectrum of index products to their clients which include asset managers, investment banks and ETF providers around the world.

Website:  www.solactive.com

About Horizons US Marijuana Index ETF (NEO: HMUS)
HMUS seeks to replicate, to the extent possible, the performance of the US Marijuana Companies Index, net of expenses. The US Marijuana Companies Index is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the United States marijuana or hemp industries.

Website:  www.horizonsetfs.com/ETF/HMUS

www.prnewswire.com/news-releases/...g-facility-301362659.html

Hollister Biosciences Inc. Announces 30-Acre Arizona Brand Campus with planned 700,000 square feet of cultivation area and an existing 28,500-square-foot processing and manufacturing facility ...

Dieser Satz ist für mich sehr interessant... Payment "with cash on hand"

"The estimated capital costs associated with phase one will be $3,000,000 and will be funded with cash on hand"

Gute Aussichten für die Q2 Zahlen und für 2021

Q2-Results 2021
Revenue 17.58 Mio. $
Gross Profit 4.32 Mio. $

6 months 2021
Revenue 40.67 Mio. $
Gross Profit 7.92 Mio. $

Segments

Arizona 6 months 2021
Revenue 40.16 Mio. $
Net income 7.25 Mio. $

California 6 months 2021
Revenue 0.51 Mio. $
Net income - 0.96 Mio. $ loss

It is easy to see that Hollister is focusing on more profit in Q2. The quantity is not the decisive factor, but the margin. There's a lot of investment going on in California and it's soon starting to run like Arizona. Great development and very good plans for 2022

www.prnewswire.com/news-releases/...ted-ebitda-301363610.html